Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3998 - Impact of prior treatment on palbociclib plus letrozole (P+L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2–) first-line advanced breast cancer (ABC): a PALOMA-2 subgroup analysis


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Breast Cancer


Richard Finn


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


R.S. Finn1, K.A. Gelmon2, J. Ettl3, J. Asselah4, A. Castrellon5, A. Ruiz Simón6, A.A. Joy7, D. Lu8, E.R. Gauthier9, A. Mori10, H.S. Rugo11, V. Diéras12

Author affiliations

  • 1 Department Of Medicine, Division Of Hematology/oncology, David Geffen School of Medicine at UCLA, 90095 - Santa Monica/US
  • 2 Department Of Medical Oncology, British Columbia Cancer Agency, V5Z 4E6 - Vancouver/CA
  • 3 Frauenklinik Und Poliklinik Klinikum Rechts Der Isar, Technische Universität München, Munich/DE
  • 4 Department Of Oncology, McGill University Health Centre, Montreal/CA
  • 5 Breast Cancer Center, Memorial Healthcare System, 33021 - Hollywood/US
  • 6 Medical Oncology, Fundación Instituto Valenciano Oncología, València/ES
  • 7 Cross Cancer Institute, University of Alberta, Edmonton/CA
  • 8 Clinical Oncology, Pfizer Inc, La Jolla/US
  • 9 Clinical Oncology, Pfizer Inc, San Francisco/US
  • 10 Clinical Oncology, Pfizer S.r.l., Milan/IT
  • 11 Department Of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco/US
  • 12 Department Of Medical Oncology, Center Eugène Marquis, Rennes/FR


Abstract 3998


PALOMA-2 confirmed the efficacy and safety of P+L vs placebo (PBO)+L in pts with treatment-naive ER+/HER2– ABC (Finn NEJM, 2016). Here, we report efficacy and safety among P+L-treated pts in 2 subgroups of either exposed or not exposed to prior neo(adjuvant) endocrine therapy (ET) and/or chemotherapy (CT).


Postmenopausal women (N = 666) were randomized 2:1 to receive P (125 mg QD; 3 wk on, 1 wk off) + L (2.5 mg QD; continuously) or PBO+L. Prior neo(adjuvant) ET/CT with curative intent was allowed; prior ET or CT for recurrent advanced or metastatic disease was not. The primary endpoint was investigator-assessed progression-free survival (PFS); other key endpoints included response rates and safety. Exposure to P among subgroups is also presented.


At baseline, 249/444 pts (56%) in the P+L arm had received prior ET and 213 (48%) had received prior CT (Table). Pts previously treated were slightly younger vs those not previously treated. Exposure to P+L was similar across subgroups. In P+L-treated pts, median PFS was 22.2/25.7 mo with prior ET/no prior ET and 22.4/25.7 mo for prior CT/no prior CT. The significant clinical benefit of P+L vs PBO+L remained regardless of prior ET/CT exposure. Across all subgroups, the incidence of all-causality adverse events (AEs) was similar; neutropenia was the most frequent AE. AEs leading to permanent discontinuation occurred in 


Regardless of prior (neo)adjuvant treatment, P+L significantly prolonged PFS vs PBO+L and demonstrated consistent efficacy in pre-treated and non–pre-treated subgroups of postmenopausal pts with ER+/HER2– ABC. Tolerability was similar across subgroups and consistent with the known safety profile of P.

Clinical trial identification


Legal entity responsible for the study





R.S. Finn: Honoraria: Bayer, Pfizer, Bristol-Myers Squibb, Novartis, Eisai; Consulting or advisory role: Pfizer, Bayer, Novartis, Bristol-Myers Squibb, Merck; Research funding Pfizer. K.A. Gelmon: Consulting or advisory role: Pfizer, Novartis, AstraZeneca, NanoString Technologies, Merck. J. Ettl: Honoraria: Pfizer, Novartis, Roche; Consulting or advisory role: Pfizer, Novartis Pharma KK; Speakers’ bureau: Pfizer, Novartis, Roche, Celgene. J. Asselah: Consulting or advisory role: Pfizer, Novartis. A. Castrellon: Research funding: Novartis; Consulting or advisory role: Biotheranostics. A. Ruiz Simón: Honoraria: Pfizer, Novartis, Roche. A.A. Joy: Consulting or advisory role: Pfizer, Novartis, Roche, Eli Lilly, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingleheim. D. Lu, E.R. Gauthier, A. Mori: Pfizer employee and shareholder. H.S. Rugo: Speakers’ bureau and honoraria: Genomic health; Research funding (Plexxikon Macrogenics, OBI Pharma, Eisai, Pfizer, Novartis, Eli Lilly, GlaxoSmithKline, Genentech, Celsion, Merck, Clovis Oncology. V. Diéras: Consulting and advisory role: Genentech, Lilly, Pfizer, AbbVie, Novartis Pharma KK, Roche-Peru; Speakers’ bureau: Pfizer, Novartis Pharma KK, Roche-Peru.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.